Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives

Show full item record



Permalink

http://hdl.handle.net/10138/333692

Citation

Guryanov, I.; Tennikova, T.; Urtti, A. Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives. Pharmaceutics 2021, 13, 1337.

Title: Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives
Author: Guryanov, Ivan; Tennikova, Tatiana; Urtti, Arto
Publisher: Multidisciplinary Digital Publishing Institute
Date: 2021-08-26
URI: http://hdl.handle.net/10138/333692
Abstract: Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs.


Files in this item

Total number of downloads: Loading...

Files Size Format View
pharmaceutics-13-01337.pdf 4.831Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record